Nanjing Legend Biotech Co.
Quick facts
Phase 1 pipeline
- LCAR-AIO T cells
- LCAR- F33S cells intravenous infusion
- LUCAR-DKS1 NK cells
- LUCAR-G79 T cells
- LUCAR-G79D T cells
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: